The role of radionuclide probes for monitoring anti-tumor drugs efficacy: A brief review

Publication date: November 2017
Source:Biomedicine & Pharmacotherapy, Volume 95
Author(s): Renata Salgado Fernandes, Carolina de Aguiar Ferreira, Daniel Cristian Ferreira Soares, Anna Margherita Maffione, Danyelle M. Townsend, Domenico Rubello, André Luís Branco de Barros
Despite recent advances in the development of new therapeutic agents and diagnostic imaging modalities, cancer is still one of the main causes of death worldwide. A better understanding of the molecular signature of cancer has promoted the development of a new generation of anti-cancer drugs and diagnostic agents that specifically target molecular components such as genes, ligands, receptors and signaling pathways. However, intrinsic heterogeneity of tumors has hampered the overall success of target therapies even among patients with similar tumor types but unpredictable different responses to therapy. In this sense, post-treatment response monitoring becomes indispensable and nuclear medicine imaging modalities could provide the tools for an early indication of therapeutic efficacy. Herein, we briefly discuss the current role of PET and SPECT imaging in monitoring cancer therapy together with an update on the current radiolabeled probes that are currently investigated for tumor therapy response assessment.



http://ift.tt/2jnQGsK